INTERESTED IN THIS RESEARCH?
Contact our analysts for inquiries, samples, and expert insights.
REPORT OUTLOOK
| Market Size | CAGR | Dominating Region |
|---|---|---|
| USD 10.50 billion | 6.4% | Europe |
| By Disease Type | By Technology | By Region |
|---|---|---|
|
|
|
SCOPE OF THE REPORT
Hereditary Testing Market Overview
The global hereditary testing market size was valued at USD 6 billion in 2020 and is projected to register at a CAGR of 6.4% and expected to reach at USD 10.50 billion in 2029 during the forecast period 2022 to 2029.
In genetic testing, specific inherited variations within an individual’s genes undergo alteration. These genetic variations can have varied effects on the likelihood of developing diseases, ranging from negative to positive, neutral, or ambiguous. There is evidence indicating that certain genes with harmful mutations increase the risk of cancer development, accounting for an estimated 5 to 10% of all cancer cases.
Cancer, a genetic disorder, arises from distinct gene alterations that regulate cell functions, particularly influencing their growth and replication. Approximately 5–10% of cancer cases stem from hereditary genetic mutations. Researchers have associated mutations in specific genes with over 50 hereditary cancer syndromes, predisposing individuals to certain types of cancer.
Breast cancer stands as one of the most prevalent cancers globally, affecting nearly 12.5% of women during their lifetime, with 5%–10% having a hereditary form. While BRCA1 and BRCA2 genes are the most commonly mutated, additional genes linked to hereditary breast cancer continue to emerge. Advancements in genomic technologies have enabled simultaneous testing of multiple genes.
Genetic mutations play a crucial role in early detection of hereditary cancer, thereby driving market growth. Concurrently, factors such as efficiency and cost-effectiveness compared to traditional testing methods contribute to market expansion. Furthermore, there is increasing demand for accurate initial detection and precise analysis, further propelling market growth.
The burgeoning field of reproductive genetic health serves as a significant market driver. Major players like Natera report a consistent rise in test volumes for women’s health genetic testing for inherited conditions, reflecting growing public acceptance of hereditary tests and accelerating revenue growth. However, the COVID-19 pandemic had a detrimental impact on the market, with governments worldwide implementing lockdowns and social distancing measures, leading to disruptions, challenges, and adjustments across industries.
Hereditary Testing Market Segment Analysis
Hereditary testing market is broadly classified into disease type, technology and region. Based on disease type, the market is further segmented into hereditary cancer testing and hereditary non-cancer testing. Based on disease type, the cancer hereditary testing category is predicted to grow at fastest rate. The number of product and service options for various hereditary cancer diagnostics continues to expand. The quick introduction of large corporations, such as Quest, into this field has exploded the genetic testing industry. Businesses are concentrating on commercial strategies to strengthen their position in this field, considering breast cancer genomic screening as a lucrative revenue stream.
Based on technology, the molecular hereditary testing category had 54.2 percent of the revenue market share, and this dominance is likely to continue during the forecast period. The fact that genetic analysis is the most extensively used tool for hereditary genetic screening accounts for the market’s growth.
Hereditary Testing Market Key Players
Some of the major market players operating in the global hereditary testing market are Agilent Technologies, Inc., Centogene N.V., CooperSurgical, Inc., F. Hoffmann-La Roche Ltd, Fulgent Genetics, Inc., Illumina, Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Medgenome, Myriad Genetics, Inc., Natera, Inc., Quest Diagnostics Incorporated, Sophia Genetics, Thermo Fisher Scientific, Inc, and Twist Bioscience.
- Agilent is a leader in life sciences, diagnostics and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling customers to gain the insights they seek.
- CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients. CENTOGENE is a world leader in the field of genetic diagnostics for rare diseases dedicated to improve patients’ lives every day.
- CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics.
Who Should Buy? Or Key stakeholders
- Healthcare Industry
- Pharmaceutical Industry
- Hospitals and Clinics
- Medical Laboratories
- Investors
- Manufacturing companies
- Scientific Research and Development
- End user companies
- Others
Key Takeaways:
- The global hereditary testing market size is projected to register at a CAGR of 6.4%
- Based on disease type, the cancer hereditary testing category is predicted to grow at fastest rate.
- Based on technology, the molecular hereditary testing category had 54.2 percent of the revenue market share.
- Europe is predicted to provide the greatest revenue market share.
- The hereditary testing market is witnessing a growing trend towards increased adoption and innovation.
Hereditary Testing Market Regional Analysis
The global hereditary testing market by region includes North America, Asia-Pacific (APAC), Europe, South America, and Middle East & Africa (MEA).
- North America: includes the US, Canada, Mexico
- Asia Pacific: includes China, Japan, South Korea, India, Australia, ASEAN and Rest of APAC
- Europe: includes UK, Germany, France, Italy, Spain, Russia, and Rest of Europe
- South America: includes Brazil, Argentina and Rest of South America
- Middle East & Africa: includes Turkey, UAE, Saudi Arabia, South Africa, and Rest of MEA
Europe is predicted to provide the greatest revenue market share, and this dominance is expected to continue throughout the forecast period. It can be attributed to the existence of large companies that offer genetic tests, the widespread use of modern medications, and government regulations that ensure the integrity of hereditary testing screening. The North American market is expected to account for a major portion of global sales. Numerous regulatory regimes, a high frequency and awareness of the negative impacts and financial significance of genetic disorders, and commercial acceptance of hereditary testing are all factors in the region’s growth.
Key Market Segments: Hereditary Testing Market
Hereditary Testing Market By Disease Type, 2020-2029, (USD Million)
- Hereditary Cancer Testing
- Hereditary Non-Cancer Testing
Hereditary Testing Market By Technology, 2020-2029, (USD MILLION)
- Cytogenetic
- Biochemical
- Molecular Testing
Hereditary Testing Market By Region, 2020-2029, (USD Million)
- North America
- Europe
- Asia Pacific
- South America
- Middle East And Africa
Important Countries In All Regions Are Covered.
Key Question Answered
- What are the growth opportunities related to the adoption of hereditary testing across major regions in the future?
- What are the new trends and advancements in the hereditary testing market?
- Which product categories are expected to have highest growth rate in the hereditary testing market?
- Which are the key factors driving the hereditary testing market?
- What will the market growth rate, growth momentum or acceleration the market carries during the forecast period?
Table of Content
- Introduction
- Market Definition
- Market Segmentation
- Research Timelines
- Assumptions and Limitations
- Research Methodology
- Data Mining
- Secondary Research
- Primary Research
- Subject-Matter Experts’ Advice
- Quality Checks
- Final Review
- Data Triangulation
- Bottom-Up Approach
- Top-Down Approach
- Research Flow
- Data Sources
- Data Mining
- Executive Summary
- Market Overview
- Global Hereditary Testing Market Outlook
- Market Drivers
- Market Restraints
- Market Opportunities
- Impact of Covid-19 On Hereditary Testing Market
- Porter’s five forces model
- Threat from new entrants
- Threat from substitutes
- Bargaining power of suppliers
- Bargaining power of customers
- Degree of competition
- Industry value chain Analysis
- Global Hereditary Testing Market Outlook
- Global Hereditary Testing Market by Disease Type (USD Million)
- Hereditary Cancer Testing
- Hereditary Non-Cancer Testing
- Global Hereditary Testing Market by Technology (USD Million)
- Cytogenetic
- Biochemical
- Molecular Testing
- Global Hereditary Testing Market by Region (USD Million)
- North America
- US
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Colombia
- Rest Of South America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest Of Europe
- Asia Pacific
- India
- China
- Japan
- South Korea
- Australia
- South-East Asia
- Rest Of Asia Pacific
- Middle East and Africa
- UAE
- Saudi Arabia
- South Africa
- Rest Of Middle East and Africa
- North America
- Company Profiles* (Business Overview, Company Snapshot, Products Offered, Recent Developments)
- Agilent Technologies, Inc.
- Centogene N.V.
- CooperSurgical, Inc.
- Hoffmann-La Roche Ltd
- Fulgent Genetics, Inc., Illumina, Inc.
- Invitae Corporation
- Laboratory Corporation of America Holdings
- Medgenome
- Myriad Genetics, Inc.
- Natera, Inc.
*The Company List Is Indicative
LIST OF TABLES
TABLE 1 Â Â Â Â Â Â Â Â Â Â Â Â Â Â GLOBAL HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 2 Â Â Â Â Â Â Â Â Â Â Â Â Â Â GLOBAL HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 3 Â Â Â Â Â Â Â Â Â Â Â Â Â Â GLOBAL HEREDITARY TESTING MARKET BY REGION (USD MILLIONS) 2020-2029
TABLE 4 Â Â Â Â Â Â Â Â Â Â Â Â Â Â US HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 5 Â Â Â Â Â Â Â Â Â Â Â Â Â Â US HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 6 Â Â Â Â Â Â Â Â Â Â Â Â Â Â CANADA HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 7 Â Â Â Â Â Â Â Â Â Â Â Â Â Â CANADA HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 8 Â Â Â Â Â Â Â Â Â Â Â Â Â Â MEXICO HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 9 Â Â Â Â Â Â Â Â Â Â Â Â Â Â MEXICO HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 10Â Â Â Â Â Â Â Â Â Â Â Â BRAZIL HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 11Â Â Â Â Â Â Â Â Â Â Â Â BRAZIL HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 12Â Â Â Â Â Â Â Â Â Â Â Â ARGENTINA HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 13Â Â Â Â Â Â Â Â Â Â Â Â ARGENTINA HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 14Â Â Â Â Â Â Â Â Â Â Â Â COLOMBIA HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 15Â Â Â Â Â Â Â Â Â Â Â Â COLOMBIA HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 16Â Â Â Â Â Â Â Â Â Â Â Â REST OF SOUTH AMERICA HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 17Â Â Â Â Â Â Â Â Â Â Â Â REST OF SOUTH AMERICA HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 18Â Â Â Â Â Â Â Â Â Â Â Â INDIA HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 19Â Â Â Â Â Â Â Â Â Â Â Â INDIA HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 20Â Â Â Â Â Â Â Â Â Â Â Â CHINA HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 21Â Â Â Â Â Â Â Â Â Â Â Â CHINA HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 22Â Â Â Â Â Â Â Â Â Â Â Â JAPAN HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 23Â Â Â Â Â Â Â Â Â Â Â Â JAPAN HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 24Â Â Â Â Â Â Â Â Â Â Â Â SOUTH KOREA HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 25Â Â Â Â Â Â Â Â Â Â Â Â SOUTH KOREA HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 26Â Â Â Â Â Â Â Â Â Â Â Â AUSTRALIA HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 27Â Â Â Â Â Â Â Â Â Â Â Â AUSTRALIA HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 28Â Â Â Â Â Â Â Â Â Â Â Â SOUTH-EAST ASIA HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 29Â Â Â Â Â Â Â Â Â Â Â Â SOUTH-EAST ASIA HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 30Â Â Â Â Â Â Â Â Â Â Â Â REST OF ASIA PACIFIC HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 31Â Â Â Â Â Â Â Â Â Â Â Â REST OF ASIA PACIFIC HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 32Â Â Â Â Â Â Â Â Â Â Â Â GERMANY HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 33Â Â Â Â Â Â Â Â Â Â Â Â GERMANY HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 34Â Â Â Â Â Â Â Â Â Â Â Â UK HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 35Â Â Â Â Â Â Â Â Â Â Â Â UK HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 36Â Â Â Â Â Â Â Â Â Â Â Â FRANCE HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 37Â Â Â Â Â Â Â Â Â Â Â Â FRANCE HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 38Â Â Â Â Â Â Â Â Â Â Â Â ITALY HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 39Â Â Â Â Â Â Â Â Â Â Â Â ITALY HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 40Â Â Â Â Â Â Â Â Â Â Â Â SPAIN HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 41Â Â Â Â Â Â Â Â Â Â Â Â SPAIN HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 42Â Â Â Â Â Â Â Â Â Â Â Â RUSSIA HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 43Â Â Â Â Â Â Â Â Â Â Â Â RUSSIA HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 44Â Â Â Â Â Â Â Â Â Â Â Â REST OF EUROPE HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 45Â Â Â Â Â Â Â Â Â Â Â Â REST OF EUROPE HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 46Â Â Â Â Â Â Â Â Â Â Â Â UAE HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 47Â Â Â Â Â Â Â Â Â Â Â Â UAE HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 48Â Â Â Â Â Â Â Â Â Â Â Â SAUDI ARABIA HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 49Â Â Â Â Â Â Â Â Â Â Â Â SAUDI ARABIA HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 50Â Â Â Â Â Â Â Â Â Â Â Â SOUTH AFRICA HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 51Â Â Â Â Â Â Â Â Â Â Â Â SOUTH AFRICA HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 52Â Â Â Â Â Â Â Â Â Â Â Â REST OF MIDDLE EAST AND AFRICA HEREDITARY TESTING MARKET BY DISEASE TYPE (USD MILLIONS) 2020-2029
TABLE 53Â Â Â Â Â Â Â Â Â Â Â Â REST OF MIDDLE EAST AND AFRICA HEREDITARY TESTING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
LIST OF FIGURES
FIGURE 1Â Â Â Â Â Â Â MARKET DYNAMICS
FIGURE 2Â Â Â Â Â Â Â MARKET SEGMENTATION
FIGURE 3Â Â Â Â Â Â Â REPORT TIMELINES: YEARS CONSIDERED
FIGURE 4Â Â Â Â Â Â Â DATA TRIANGULATION
FIGURE 5Â Â Â Â Â Â Â BOTTOM-UP APPROACH
FIGURE 6Â Â Â Â Â Â Â TOP-DOWN APPROACH
FIGURE 7Â Â Â Â Â Â Â RESEARCH FLOW
FIGURE 8Â Â Â Â Â Â Â GLOBAL HEREDITARY TESTING MARKET BY DISEASE TYPE, USD MILLION, 2020-2029
FIGURE 9Â Â Â Â Â Â Â GLOBAL HEREDITARY TESTING MARKET BY TECHNOLOGY, USD MILLION, 2020-2029
FIGURE 10Â Â Â Â Â GLOBAL HEREDITARY TESTING MARKET BY TECHNOLOGY, USD MILLION, 2020-2029
FIGURE 11Â Â Â Â Â GLOBAL HEREDITARY TESTING MARKET BY REGION, USD MILLION, 2020-2029
FIGURE 12     PORTER’S FIVE FORCES MODEL
FIGURE 13Â Â Â Â Â NORTH AMERICA HEREDITARY TESTING MARKET SNAPSHOT
FIGURE 14Â Â Â Â Â EUROPE HEREDITARY TESTING MARKET SNAPSHOT
FIGURE 15Â Â Â Â Â ASIA PACIFIC HEREDITARY TESTING MARKET SNAPSHOT
FIGURE 16Â Â Â Â Â SOUTH AMERICA HEREDITARY TESTING MARKET SNAPSHOT
FIGURE 17Â Â Â Â Â MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SNAPSHOT
FIGURE 18Â Â Â Â Â AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
FIGURE 19Â Â Â Â Â CENTOGENE N.V.: COMPANY SNAPSHOT
FIGURE 20Â Â Â Â Â COOPERSURGICAL, INC.: COMPANY SNAPSHOT
FIGURE 21Â Â Â Â Â F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
FIGURE 22Â Â Â Â Â FULGENT GENETICS, INC., ILLUMINA, INC.: COMPANY SNAPSHOT
FIGURE 23Â Â Â Â Â INVITAE CORPORATION: COMPANY SNAPSHOT
FIGURE 24Â Â Â Â Â LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
FIGURE 25Â Â Â Â Â MEDGENOME: COMPANY SNAPSHOT
FIGURE 26Â Â Â Â Â MYRIAD GENETICS, INC.: COMPANY SNAPSHOT
FIGURE 27Â Â Â Â Â NATERA, INC.: COMPANY SNAPSHOT
In-Depth Database
Our Report’s database covers almost all topics of all regions over the Globe.
Recognised Publishing Sources
Tie ups with top publishers around the globe.
Customer Support
Complete pre and post sales
support.
Safe & Secure
Complete secure payment
process.